OLINVYK：市場規模・予測・市場洞察 (～2032年)

当レポートでは、主要7カ国 (米国、EU4カ国 (ドイツ、フランス、イタリア、スペイン)、英国、日本) における術後疼痛治療薬 OLINVYKの動向を調査し、治療薬の概要、作用機序、臨床開発データ、関連法規制、上市済みおよび開発中の薬剤との競合分析、国別の市場規模の推移・予測、SWOT分析、アナリストの見解などをまとめています。

レポートハイライト：

• 術後疼痛の市場シナリオは、広範な研究と医療支出の増加により今後数年間で変化すると考えられています。
• 各社は、疾患を治療・改善し、課題を評価し、OLINVYKの優位性に影響を与えられる機会を得るため、新しいアプローチに焦点を当てた治療薬の開発を行っています。
• 他の新興術後疼痛治療薬がOLINVYKと厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与える見通しです。
• 法規制上のマイルストーンと開発活動の詳細な説明により、術後疼痛におけるOLINVYKの現在の開発シナリオを提供します。
• 2024年から2032年までのOLINVYKの予測販売データの詳細な分析により、術後疼痛におけるOLINVYKの全体的なシナリオを明らかにし、治療薬ポートフォリオに関する意思決定プロセスを支援します。

目次

第1章 レポートイントロダクション

第2章 術後疼痛におけるOLINVYKの概要

• 製品詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢 (上市済み治療薬)

第4章 競合情勢 (後期段階の新興治療薬)

第5章 OLINVYK：市場評価

• 術後疼痛に対するOLINVYK：市場展望
• 主要7カ国の分析
  • 術後疼痛治療薬OLINVYKの市場規模
• 国別市場分析
  • 市場規模：米国
  • 市場規模：ドイツ
  • 市場規模：英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: OLINVYK, Clinical Trial Description, 2023
• Table 2: OLINVYK, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: OLINVYK Market Size in the 7MM, in USD million (2019-2032)
• Table 6: OLINVYK Market Size in the US, in USD million (2019-2032)
• Table 7: OLINVYK Market Size in Germany, in USD million (2019-2032)
• Table 8: OLINVYK Market Size in France, in USD million (2019-2032)
• Table 9: OLINVYK Market Size in Italy, in USD million (2019-2032)
• Table 10: OLINVYK Market Size in Spain, in USD million (2019-2032)
• Table 11: OLINVYK Market Size in the UK, in USD million (2019-2032)
• Table 12: OLINVYK Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: OLINVYK Market Size in the 7MM, USD million (2019-2032)
• Figure 2: OLINVYK Market Size in the United States, USD million (2019-2032)
• Figure 3: OLINVYK Market Size in Germany, USD million (2019-2032)
• Figure 4: OLINVYK Market Size in France, USD million (2019-2032)
• Figure 5: OLINVYK Market Size in Italy, USD million (2019-2032)
• Figure 6: OLINVYK Market Size in Spain, USD million (2019-2032)
• Figure 7: OLINVYK Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: OLINVYK Market Size in Japan, USD million (2019-2032)

"OLINVYK Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about OLINVYK for Postoperative pain in the seven major markets. A detailed picture of the OLINVYK for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the OLINVYK for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the OLINVYK market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

OLINVYK (oliceridine) is an opioid agonist indicated in adults for managing acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The company announced the commercial launch of OLINVYK in February 2021. It is a new chemical entity with a novel mechanism of action at the MOR that enables more selective targeting of newly discovered pathways with the potential for fewer side effects.

Dosage and administration

OLINVYK 30 mg/30 mL (1 mg/mL) vial is intended for patient-controlled analgesia (PCA) use only. The cumulative daily dose should not exceed 27 mg.

Mechanism of action

Oliceridine is a full opioid agonist and is relatively selective for the mu-opioid receptor. The principal therapeutic action of oliceridine is analgesia. Clinically, the dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.

The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain, and spinal cord and are thought to play a role in the analgesic effects of this drug.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the OLINVYK description, mechanism of action, dosage and administration, research and development activities in Postoperative pain.
• Elaborated details on OLINVYK regulatory milestones and other development activities have been provided in this report.
• The report also highlights the OLINVYK research and development activities in Postoperative pain across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around OLINVYK.
• The report contains forecasted sales of OLINVYK for Postoperative pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain.
• The report also features the SWOT analysis with analyst views for OLINVYK in Postoperative pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

OLINVYK Analytical Perspective by DelveInsight

• In-depth OLINVYK Market Assessment

This report provides a detailed market assessment of OLINVYK for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• OLINVYK Clinical Assessment

The report provides the clinical trials information of OLINVYK for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Postoperative pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OLINVYK dominance.
• Other emerging products for Postoperative pain are expected to give tough market competition to OLINVYK and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OLINVYK in Postoperative pain.
• Our in-depth analysis of the forecasted sales data of OLINVYK from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the OLINVYK in Postoperative pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of OLINVYK?
• What is the clinical trial status of the study related to OLINVYK in Postoperative pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OLINVYK development?
• What are the key designations that have been granted to OLINVYK for Postoperative pain?
• What is the forecasted market scenario of OLINVYK for Postoperative pain?
• What are the forecasted sales of OLINVYK in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to OLINVYK for Postoperative pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain?

Table of Contents

1. Report Introduction

2. OLINVYK Overview in Postoperative pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. OLINVYK Market Assessment

• 5.1. Market Outlook of OLINVYK in Postoperative pain
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of OLINVYK in the 7MM for Postoperative pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of OLINVYK in the United States for Postoperative pain
  • 5.3.2. Market Size of OLINVYK in Germany for Postoperative pain
  • 5.3.3. Market Size of OLINVYK in France for Postoperative pain
  • 5.3.4. Market Size of OLINVYK in Italy for Postoperative pain
  • 5.3.5. Market Size of OLINVYK in Spain for Postoperative pain
  • 5.3.6. Market Size of OLINVYK in the United Kingdom for Postoperative pain
  • 5.3.7. Market Size of OLINVYK in Japan for Postoperative pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options